|
| Press Releases |
|
 |
|
| Wednesday, July 16, 2025 |
|
|
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the drug discovery research for Lecanemab (product name: "LEQEMBI"), a humanized anti-human soluble amyloid B (AB) protofibril monoclonal antibody indicated for early Alzheimer's disease (early AD*), which was co-developed by Eisai and BioArctic AB (Headquarters: Sweden; herein after, BioArctic), has received "The 9th Bioindustry Award" from the Japan Bioindustry Association (JBA). more info >> |
|
| Monday, July 14, 2025 |
|
|
"URECE" (Dotinurad) Launched in China as a treatment for Gout |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has launched "URECE" (brand name in China: "Youlesi", generic name: dotinurad) in China as a treatment for Gout. more info >> |
|
| Tuesday, July 8, 2025 |
|
|
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced that it has been selected for the highest rating of "Supplier Engagement Leader" in the Supplier Engagement Rating by the global environmental non-profit organization CDP. more info >> |
|
| Monday, June 2, 2025 |
|
|
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan |
| Eisai Co., Ltd. announced today the launch of "Pariet S" (pharmaceutical requiring guidance), which is highly effective in alleviating severe heartburn andstomach pain caused by gastric acid reflux, at pharmacies and drugstores throughout Japan.(1) more info >> |
|
| Wednesday, May 28, 2025 |
|
|
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China |
| Eisai Co., Ltd. announced today that the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) has been approved in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
| Wednesday, May 21, 2025 |
|
|
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025 |
| Eisai Co., Ltd. announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO25), which is taking place in Chicago, Illinois, and virtually,from May 30 to June 3. more info >> |
|
| Friday, May 16, 2025 |
|
|
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro |
| Eisai Co., Ltd. announced today that it has received notification from Japan's Ministry of Health, Labour, and Welfare (MHLW) that the "all-case surveillance" post-marketing observational study condition required at the time of approval of anticancer agent "Remitoro for Intravenous Drip Infusion 300microgram" (Denileukin Diftitox (Genetical Recombination)) for the indications of T-cell Lymphoma has been cleared. more info >> |
|
| Wednesday, April 30, 2025 |
|
|
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star |
| Eisai Co., Ltd. announced today that its Representative Corporate Officer and CEO Haruo Naito has been selected to receive the Order of the Rising Sun, Gold and Silver Star at the 2025 Spring Conferment of Decorations. more info >> |
|
| Friday, April 18, 2025 |
|
|
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union |
| Eisai Co., Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) Marketing Authorization (MA) in the European Union (EU). more info >> |
|
| Tuesday, April 1, 2025 |
|
|
Eisai to Divest Rights for Pariet in China to Peak Pharma |
| Eisai Co., Ltd. announced today that it has entered into an agreement to divest the rights for proton pump inhibitor Pariet (generic name: rabeprazole sodium) in China to Beijing Peak Biology Pharmaceuticals Co., Ltd., a CBC Group-controlled company. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
DK88 Casino Officially Launches in Malaysia 
Feb 21, 2026 21:50 HKT/SGT
|
|
|
Graphene Manufacturing Group and Tickford Racing Unite to Push Performance Efficiency On and Off the Track
Feb 20, 2026 20:59 HKT/SGT
|
|
|
Full Convertible Bond Conversion Removes Overhang and Signals Valuation Reassessment for Shoucheng Holdings
Feb 20, 2026 20:32 JST
|
|
|
Investee Companies Take the National Stage: Shoucheng Holdings' 'Capital+Scenario+Industry Chain' Strategy Validated, Entering the Value Realization Phase
Feb 20, 2026 20:06 JST
|
|
|
Hong Kong designer labels shine at London Fashion Week
Feb 20, 2026 17:04 HKT/SGT
|
|
|
Spritzer EcoPark Champions Inclusive Experiences in Nature Through Meaningful Community Engagement
Feb 20, 2026 15:37 HKT/SGT
|
|
|
Shoucheng Holdings Draws Focus After Portfolio Companies Appear in Spring Festival Gala Robotics Showcase
Feb 20, 2026 15:29 HKT/SGT
|
|
|
Hitachi Rail Invests C$30 Million in New Canadian Headquarters
Feb 20, 2026 12:20 JST
|
|
|
The Capital Architect Behind the Gala Robots: Shoucheng Holdings (0697.HK) Enters a Milestone Year of Value Re-rating
Feb 20, 2026 09:11 HKT/SGT
|
|
|
Toyota Launches New RAV4 (PHEV) in Japan
Feb 19, 2026 19:25 JST
|
|
|
Osaka Hospital launches project to safely utilize generative AI for healthcare workforce improvements
Feb 19, 2026 12:12 JST
|
|
|
Asia's Protein Buyers Still Trail Global Best Practice -- But Momentum is Building, New ARE Benchmark Finds
Feb 19, 2026 11:02 HKT/SGT
|
|
|
CDAO Sydney 2026 Announces Two-Day, Co Located Event Series Uniting Australia's Senior Data & AI Leaders
Feb 18, 2026 17:17 HKT/SGT
|
|
|
India's Power Transition Creates Clear Utility Divide
Feb 18, 2026 16:00 HKT/SGT
|
|
|
MHI Machinery Systems Participates in Ramp Merging Support Demonstration Experiment for Autonomous Vehicles on the Tokyo Metropolitan Expressway
Feb 18, 2026 15:37 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
